Faculty Opinions recommendation of GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.

Author(s):  
Michael Schön
2007 ◽  
Vol 21 (5) ◽  
Author(s):  
Lei Xu ◽  
Shahinoor Begum ◽  
Jeremy D Hearn ◽  
Richard O Hynes

2012 ◽  
Vol 187 (1) ◽  
pp. 322-329 ◽  
Author(s):  
Jae Il Kim ◽  
Prabir Chakraborty ◽  
Zhimin Wang ◽  
Yehia Daaka

2010 ◽  
Vol 70 (2) ◽  
pp. 772-781 ◽  
Author(s):  
Wa Du ◽  
Noriko Takuwa ◽  
Kazuaki Yoshioka ◽  
Yasuo Okamoto ◽  
Koichi Gonda ◽  
...  

2019 ◽  
Vol 20 (3) ◽  
pp. 559 ◽  
Author(s):  
Shu Z. Wiley ◽  
Krishna Sriram ◽  
Cristina Salmerón ◽  
Paul A. Insel

GPR68 (or ovarian cancer G protein-coupled receptor 1, OGR1) is a proton-sensing G-protein-coupled receptor (GPCR) that responds to extracellular acidity and regulates a variety of cellular functions. Acidosis is considered a defining hallmark of the tumor microenvironment (TME). GPR68 expression is highly upregulated in numerous types of cancer. Emerging evidence has revealed that GPR68 may play crucial roles in tumor biology, including tumorigenesis, tumor growth, and metastasis. This review summarizes current knowledge regarding GPR68—its expression, regulation, signaling pathways, physiological roles, and functions it regulates in human cancers (including prostate, colon and pancreatic cancer, melanoma, medulloblastoma, and myelodysplastic syndrome). The findings provide evidence for GPR68 as a potentially novel therapeutic target but in addition, we note challenges in developing drugs that target GPR68.


2020 ◽  
Author(s):  
Debbie C. Crans ◽  
Duaa Althumairy ◽  
Heide Murakami ◽  
B. George Barisas ◽  
Deborah Roess

Sign in / Sign up

Export Citation Format

Share Document